NTRK1 and COVID-19: In conclusion, we found a high rate of COVID-19 vaccination among uro-oncology patients receiving systemic targeted therapy with tyrosine kinase receptor inhibitors (TKIs) for mRCC and systemic therapy with androgen receptor target agents (ARTAs) for mCRPC.